Gilead Sciences Inc. (GILD: Quote) Sunday said data from the Phase 4 Terisa study, which demonstrated that the addition of ranolazine to background antianginal therapy in chronic angina patients with type 2 diabetes significantly reduced the frequency of weekly angina episodes compared to placebo and background antianginal therapy.
Ranexa is indicated for the treatment of chronic angina. Ranexa is not indicated for the treatment of diabetes.
Chronic angina, the most common symptom of coronary artery disease, can be a debilitating heart condition. Angina typically manifests as recurrent pain or tightness in the chest upon exertion or emotional stress. Patients with diabetes have more extensive coronary artery disease and a propensity for greater angina burden compared to patients without diabetes.
Following a single-blind, four-week placebo run-in phase, 927 randomized patients received ranolazine or matching placebo in addition to background antianginal therapy for eight weeks. During weeks 2-8, average weekly angina frequency was significantly lower with ranolazine versus placebo.
Click here to receive FREE breaking news email alerts for Gilead Sciences Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News